Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
_ largest » _ large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
_ largest » _ large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
-
1
ECoG timescales decrease during spatial attention.
Published 2025“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
Published 2025“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. (B) Even though higher proportions of mutualism promote higher richness, introducing this type of interaction into already assembled large communities promotes a sudden drop in richness, while stopping mutualism promotes a slight boost in richness increase. …”
-
12
-
13
-
14
-
15
-
16
-
17
-
18
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
19
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
20
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: